Cited by 103Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesCancer-related Molecular Pathways

The DOI matches its Crossref record; 129 of the 132 references it cites were found in a registry or an index.

Current status and new treatment approaches in TP53 mutated AML

Hunter, Anthony M., Sallman, David A.·2019·Best Practice & Research Clinical Haematology

DOI 10.1016/j.beha.2019.05.004

Open this paper in CoChat — free account

Abstract

Mutations in the essential tumor suppressor gene, TP53, are observed in only 5-10% of acute myeloid leukemia (AML) cases, but are highly associated with therapy-related AML and cases with complex karyotype. The mutational status of TP53 is a critical prognostic indicator, with dismal outcomes consistently observed across studies. Response rates to traditional cytotoxic chemotherapy are poor and long-term survival after allogeneic hematopoietic stem cell transplant is rare. Therapy with hypomethylating agents has resulted in a modest improvement in outcomes over intensive chemotherapy, but durable responses are seldom observed. In view of the intrinsic resistance to standard chemotherapies conferred by mutations in TP53, novel treatment approaches are required. In this review, we examine the current treatment landscape in TP53 mutated AML and discuss emerging therapeutic approaches currently under clinical investigation.

Integrity signals

Registry

Crossref · 10.1016/j.beha.2019.05.004

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Döhner, H., Estey, E. H., Grimwade, D. J., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,938
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy
Christman, J. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205699 · Cited by 1,561

Show all 132 references

Sorted by citations

Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes
Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465
“PRD (63-97) DBD (102-292) TET (323-356) REG (363-393) TAD2 (43-62) TAD1 (1-42) CR mCR + HI mCR HI SD PD NR/NE”
Self-citation
Advances in acute myeloid leukemia
Newell, L. F., & Cook, R. J. (2021) · BMJ · doi:10.1136/bmj.n2026 · Cited by 461
Unified classification and risk-stratification in Acute Myeloid Leukemia
Tazi, Y., Ossa, J. A., Zhou, Y., Bernard, E., Thomas, I., Gilkes, A., Freeman, S. D., Pradat, Y., Johnson, S. J., Hills, R. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32103-8 · Cited by 195
TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 184
Self-citation
Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax
Kim, K., Maiti, A., Loghavi, S., Pourebrahim, R., Kadia, T. M., Rausch, C. R., Furudate, K., Daver, N. G., Alvarado, Y., Ohanian, M., et al. (2021) · Cancer · doi:10.1002/cncr.33689 · Cited by 161
A concise review on the molecular genetics of acute myeloid leukemia
Padmakumar, D., Chandraprabha, V. R., Gopinath, P., Devi, A. R. T. V., Anitha, G. R. J., Sreelatha, M. M., Padmakumar, A., & Sreedharan, H. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106727 · Cited by 90
What have we learned about TP53-mutated acute myeloid leukemia?
Shahzad, M., Amin, M. K., Daver, N. G., Shah, M. V., Hiwase, D., Arber, D. A., Kharfan‐Dabaja, M. A., & Badar, T. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01186-5 · Cited by 88
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
Daver, N. G., Iqbal, S., Renard, C., Chan, R. J., Hasegawa, K., Hu, H., Tse, P., Yan, J., Zoratti, M. J., Xie, F., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01417-5 · Cited by 76
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
Eckardt, J., Röllig, C., Metzeler, K. H., Krämer, M., Stasik, S., Georgi, J.-A., Heisig, P., Spiekermann, K., Krug, U. O., Braess, J., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.280027 · Cited by 53
Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
Stengel, A., Meggendorfer, M., Walter, W., Baer, C., Nadarajah, N., Hutter, S., Kern, W., Haferlach, T., & Haferlach, C. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010312 · Cited by 53
Explainable artificial intelligence for precision medicine in acute myeloid leukemia
Gimeno, M., José‐Eneriz, E. S., Villar, S., Agirre, X., Prósper, F., Rubio, A., & Carazo, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.977358 · Cited by 57
How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines
Chaer, F. E., Hourigan, C. S., & Zeidan, A. M. (2023) · Blood · doi:10.1182/blood.2022017808 · Cited by 51
Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment
Peroni, E., Randi, M. L., Rosato, A., & Cagnin, S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02841-8 · Cited by 51
Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern
Dozzo, A., Galvin, A., Shin, J., Scalia, S., O’Driscoll, C. M., & Ryan, K. B. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01189-4 · Cited by 40
To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia
Sallman, D. A. (2020) · Haematologica · doi:10.3324/haematol.2020.249060 · Cited by 37
Self-citation
Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022
Roloff, G. W., Odenike, O. M., Bajel, A. R., Wei, A. H., Foley, N. C., & Uy, G. L. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349605 · Cited by 36
DNA methylation-based prognostic biomarkers of acute myeloid leukemia patients
Hu, L., Gao, Y., Shi, Z., Liu, Y., Zhao, J., Xiao, Z., Lou, J., Xu, Q., & Tong, X. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.122 · Cited by 32
Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS
Stengel, A., Haferlach, T., Baer, C. R., Hütter, S., Meggendorfer, M., Kern, W., & Haferlach, C. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009100 · Cited by 30
Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure
Pasquer, H., Tostain, M., Kaci, N., Roux, B., & Benajiba, L. (2021) · Cancers · doi:10.3390/cancers13040748 · Cited by 31
Advances in therapeutic options for newly diagnosed, high-risk AML patients
Doucette, K., Karp, J. E., & Lai, C. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211001138 · Cited by 25
Targeting Apoptosis in AML: Where Do We Stand?
Krawiec, K. M., Strzałka, P., Czemerska, M., Wiśnik, A., Zawlik, I., Wierzbowska, A., & Pluta, A. (2022) · Cancers · doi:10.3390/cancers14204995 · Cited by 27
The promise of macrophage directed checkpoint inhibitors in myeloid malignancies
Swoboda, D. M., & Sallman, D. A. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101221 · Cited by 25
Self-citation
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
Tahir, S. K., Calvo, E., Carneiro, B. A., Yuda, J., Shreenivas, A. V., Jongen‐Lavrencic, M., Gort, E. H., Ishizawa, K., Morillo, D., Biesdorf, C., et al. (2023) · Blood · doi:10.1182/blood.2022017333 · Cited by 26
New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
Andreozzi, F., Massaro, F., Wittnebel, S., Spilleboudt, C., Lewalle, P., & Salaroli, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073887 · Cited by 22
Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion
Daver, N. G., Iqbal, S., Huang, J. C., Renard, C., Lin, J., Pan, Y., Williamson, M., & Ramsingh, G. (2023) · American Journal of Hematology · doi:10.1002/ajh.26941 · Cited by 22
TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
Niparuck, P., Police, P., Noikongdee, P., Siriputtanapong, K., Limsuwanachot, N., Rerkamnuaychoke, B., Chuncharunee, S., & Siriboonpiputtana, T. (2021) · Diagnostic Pathology · doi:10.1186/s13000-021-01162-8 · Cited by 22
Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes
Huang, L., Lin, L., Fu, X., & Meng, C. (2021) · PeerJ · doi:10.7717/peerj.11968 · Cited by 20
Progress toward Better Treatment of Therapy-Related AML
Kotsiafti, A., Giannakas, K., Christoforou, P., & Liapis, K. (2023) · Cancers · doi:10.3390/cancers15061658 · Cited by 18
Searching for a signature involving 10 genes to predict the survival of patients with acute myelocytic leukemia through a combined multi-omics analysis
Zhuang, H., Chen, Y., Sheng, X., Hong, L., Gao, R., & Zhuang, X. (2020) · PeerJ · doi:10.7717/peerj.9437 · Cited by 16
Zebrafish models of acute leukemias: Current models and future directions
Molina, B., Chavez, J., & Grainger, S. J. (2020) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.400 · Cited by 16
Arsenic concentration in topsoil of central Chile is associated with aberrant methylation of P53 gene in human blood cells: a cross-sectional study
Eva Madrid, A., González, I., Muñoz, S., Rejas, C., Cardemil, F., Martínez, F. T., Cortes, J. P., Berasaluce, M., & Párraga, M. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-19085-2 · Cited by 13
The Prognostic Value of TP53 Mutations in Adult Acute Myeloid Leukemia: A Meta-Analysis
Qin, G., & Han, X. (2022) · Transfusion Medicine and Hemotherapy · doi:10.1159/000526174 · Cited by 11
New Treatment Options for Older Patients with Acute Myeloid Leukemia
Saxena, K., & Konopleva, M. Y. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00841-4 · Cited by 11
m 6 A RNA methylation regulators predict prognosis and indicate characteristics of tumour microenvironment infiltration in acute myeloid leukaemia
Liao, X., Chen, L., Liu, J., Hu, H., Hou, D., You, R., Wang, X., & Huang, H. (2022) · Epigenetics · doi:10.1080/15592294.2022.2160134 · Cited by 11
Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia
Chandra, D. J., Lachowiez, C. A., & Loghavi, S. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101156 · Cited by 10
Comprehensive analysis of m 6 A methylome alterations after azacytidine plus venetoclax treatment for acute myeloid leukemia by nanopore sequencing
Zhang, Z., Zhang, L., Li, J., Feng, R., Li, C., Liu, Y., Sun, G., Xiao, F., & Zhang, C. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.02.029 · Cited by 9
XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53 -mutated myeloid malignancies
Kruer, T. L., Quintana, A., Newman, H., Ferrall‐Fairbanks, M. C., Zhang, L., McLemore, A. F., Neupane, S., Yang, Q., Ben-Crentsil, N. A., Balasis, M. E., et al. (2025) · Blood · doi:10.1182/blood.2025028803 · Cited by 10
Self-citation
Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies
Czegle, I., Gray, A. L., Wang, M., Liu, Y., Wang, J., & Wappler-Guzzetta, E. A. (2021) · Life · doi:10.3390/life11121351 · Cited by 10
Recommendations for laboratory testing of UK patients with acute myeloid leukaemia
Mehta, P., Telford, N., Wragg, C., Dillon, R. J., Freeman, S. D., Finnegan, D. P. J., Hamblin, A. D., Copland, M., & Knapper, S. (2022) · British Journal of Haematology · doi:10.1111/bjh.18516 · Cited by 9
Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia
Yoshida, S. Y., Onozawa, M., Miyashita, N., Kimura, H., Takahashi, S., Yokoyama, S., Matsukawa, T., Hirabayashi, S., Mori, A., Hidaka, D., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03522-6 · Cited by 8
Identification and validation of signal recognition particle 14 as a prognostic biomarker predicting overall survival in patients with acute myeloid leukemia
Shi, L., Huang, R., & Lai, Y. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-00975-2 · Cited by 7
Cancer spectrum in TP53-deficient golden Syrian hamsters: A new model for li-fraumeni syndrome
Wang, Y., Wang, Z., Cormier, R., Miao, J., Li, R., Wettere, A. V., Guo, H., Tăbăran, F., O'Sullivan, M., Carlson, T., et al. (2021) · Journal of Carcinogenesis · doi:10.4103/jcar.jcar_18_21 · Cited by 7
CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia
Li, Q., Liang, C., Xu, X., Zhang, C., Cao, W., Wang, M., Jiang, Z., Xing, H., & Yu, J. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2064986 · Cited by 7
Exploration of molecular markers related to chemotherapy efficacy of hepatoid adenocarcinoma of the stomach
Wei, J., Ji, K., Zhang, Y., Zhang, J., Wu, X., Ji, X., Zhou, K., Yang, X., Lu, H., Wang, A., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00892-9 · Cited by 8
High Expression of RhoBTB3 Predicts Favorable Chemothrapy Outcomes in non-M3 Acute Myeloid Leukemia
Yang, S., Liu, W., Peng, J., Xu, Y., Liu, Y., Li, Y., Peng, M., Ouyang, Z., Chen, C., & Liu, E. (2021) · Journal of Cancer · doi:10.7150/jca.50472 · Cited by 7
Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia
Stafylidis, C., Vlachopoulou, D., Kontandreopoulou, C., & Diamantopoulos, P. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041082 · Cited by 6
Precision Medicine in Myeloid Malignancies: Hype or Hope?
Banskota, S. U., Khanal, N., Marar, R. I., Dhakal, P., & Bhatt, V. R. (2022) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-022-00674-4 · Cited by 6
Identification of prognostic and driver gene mutations in acute myeloid leukemia by a bioinformatics analysis
Li, L., Ruan, J., Zhang, N., Dai, J. L., Xu, X., Tian, X., & Hu, J. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-587 · Cited by 6
ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells
Valdez, B. C., Yuan, B., Murray, D. L., Ramdial, J., Popat, U., Nieto, Y. L., & Andersson, B. S. (2024) · Oncotarget · doi:10.18632/oncotarget.28563 · Cited by 5
Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations
Koolivand, Z., Bahreini, F., Rayzan, E., & Rezaei, N. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41355 · Cited by 6
p53 immunohistochemistry staining is a rapid screening method for TP53 mutation in myeloid malignancies suitable for integration into routine diagnostic laboratory practice
Nelles, R., Tallack, M. R., Tate, C., Hunt, S., Aung, H., Henden, A. S., Jones, L. V., & Seymour, L. (2025) · Pathology · doi:10.1016/j.pathol.2024.11.011 · Cited by 5
Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia
Wang, Y., Zhou, W., McReynolds, L. J., Katki, H. A., Griffiths, E. A., Thota, S., Machiela, M. J., Yeager, M., McCarthy, P. L., Pasquini, M. C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94539-0 · Cited by 5
EDUCACIÓN PARA EL BILINGÜISMO EN CONTEXTO MONOLINGÜE: DOS LENGUAS CONECTADAS DESDE EL CURRÍCULO
Ordóñez, C. L. (2010) · Elia · Cited by 5
Mutation-Driven Therapy in MDS
Swoboda, D. M., & Sallman, D. A. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00554-4 · Cited by 5
Self-citation
Is outcome of older people with acute myeloid leukemia improving with new therapeutic approaches and stem cell transplantation?
Ferrara, F., & Picardi, A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1715207 · Cited by 5
Recruiting TP53 to target chronic myeloid leukemia stem cells
Grant, S. (2020) · Haematologica · doi:10.3324/haematol.2019.246306 · Cited by 5
What’s New in the Classification, Diagnosis and Therapy of Myeloid Leukemias
Pizzi, M., Gurrieri, C., & Orazi, A. (2023) · Hemato · doi:10.3390/hemato4020011 · Cited by 4
Azacitidine combined with venetoclax alleviates AML-MR with TP53 mutation in SDS: a case report and literature review
Ma, C., Lang, H., Chen, Y., Yang, L., Wang, C., Han, L., Chen, X., & Ma, W. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001594 · Cited by 4
Evaluating targeted therapies in older patients with TP53 -mutated AML
Sabile, J. M. G., Swords, R. T., & Tyner, J. W. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2344057 · Cited by 4
Overall survival in TP53-mutated AML and MDS
Puzo, C. J., Hager, K. M., Rinder, H. M., Weinberg, O. K., & Siddon, A. J. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06054-7 · Cited by 4
Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies
Yang, G., Williams, S. A., He, F. C., He, Y., McIntyre, K., Beckman, A. K., Nelson, A., & Yohe, S. L. (2024) · Pathology · doi:10.1016/j.pathol.2023.11.009 · Cited by 4
Sensitivity of Acute Myelocytic Leukemia Cells to the Dienone Compound VLX1570 Is Associated with Inhibition of the Ubiquitin-Proteasome System
Selvaraju, K., Lotfi, K., Gubat, J., Miquel, M., Nilsson, A., Hill, J., Jensen, L. D., Linder, S. T., & D’Arcy, P. (2021) · Biomolecules · doi:10.3390/biom11091339 · Cited by 4
Targeting acute myeloid leukemia resistance with two novel combinations demonstrate superior efficacy in TP53, HLA-B, MUC4 and FLT3 mutations
Gholizadeh, E., Zangene, E., Parsons, A., Kontro, M., Heckman, C. A., & Jafari, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118647 · Cited by 3
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Eisenmann, E. D., Swords, R. T., Huang, Y., Orwick, S. J., Buelow, D. R., Abbott, N., Phelps, M. A., Zeidner, J. F., Foster, M. C., Lin, T. L., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0091 · Cited by 3
Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia
Makowka, P., Stolp, V., Stoschek, K., & Serve, H. L. (2021) · Biological Chemistry · doi:10.1515/hsz-2021-0288 · Cited by 3
Decoding the molecular drivers of TP53 ‐mutant acute myeloid leukaemia: Clinical implications and prognostic insights
Wang, L., Gao, H., Fu, Q., Jiang, Q., Jiang, H., Wang, Y., Xu, L., Zhang, X., Huang, X., & Tang, F. (2025) · British Journal of Haematology · doi:10.1111/bjh.70271 · Cited by 2
Venetoclax and azacitidine versus CAG for unfit patients with newly diagnosed acute myeloid leukemia: A propensity score-matched analysis
Chang, G., Gao, H., Wei, Y., Fu, Q., Jiang, Q., Jiang, H., Xu, L., Zhang, X., Huang, X., & Tang, F. (2026) · Leukemia Research · doi:10.1016/j.leukres.2026.108187 · Cited by 2
TP53 -mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition
Spinella, J.-F., Chagraoui, J., Boivin, I., Richard‐Carpentier, G., Moison, C., Mayotte, N., Béliveau, F., Lavallée, V., Hébert, J., & Sauvageau, G. (2026) · Science Advances · doi:10.1126/sciadv.aed7122 · Cited by 3
SNAI1: a key modulator of survival in lung squamous cell carcinoma and its association with metastasis
Li, B., & Li, R. (2024) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-024-03044-8 · Cited by 2
Treatment of minimal residual disease in myeloid malignancies after allo-HSCT with venetoclax-based regimens in patients ineligible for or failed in the immunotherapy
Yu, W., Kong, J., Zheng, F., Mo, X., Zhang, X., Xu, L., Zhang, Y., Sun, Y., Jin, J., Huang, X.-J., et al. (2024) · Hematology · doi:10.1080/16078454.2024.2418653 · Cited by 2
Az akut mieloid leukémia kezelésének új lehetőségei: út a személyre szabott terápiás stratégiák felé
Szakács, Z., & Alizadeh, H. (2022) · Hematológia–Transzfuziológia · doi:10.1556/2068.2022.00151 · Cited by 2
Pulmonary infection associated with immune dysfunction is associated with poor prognosis in patients with myelodysplastic syndrome accompanied by TP53 abnormalities
Chen, Y., Zheng, J., Qiu, Y., Wu, Z., Luo, X., Zhu, L.-F., Wu, Y. C., & Lin, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1294037 · Cited by 1
Cancer as a Disease of Defective Cell Cycle Checkpoint Function
Jackson, R. (2023) · Springer eBooks · doi:10.1007/978-3-031-32573-1_3 · Cited by 1
Role of Meningioma 1 for maintaining the transformed state in MLL-rearranged acute myeloid leukemia: potential for therapeutic intervention?
Schwaller, J. (2020) · Haematologica · doi:10.3324/haematol.2019.246348 · Cited by 1
Introduction to Cancer Treatment
Zonouzi, S. K., Razi, S., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_216-1 · Cited by 1
Comprehensive analysis of the landscape characteristics of m6A regulators in acute myeloid leukemiaPreprint
Liao, X., Chen, L., Liu, J., Hu, H., Hou, D., You, R., Wang, X., & Huang, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1511744/v1 · Cited by 1
Hematopoietic p53 loss cell-extrinsically defines an immune infiltrated microenvironment in leukemia and pre-leukemiaPreprint
Posey, R. R., Lee, J. D., Clohessy, S., Mendez, L., & Pandolfi, P. P. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.22.002774
Treatment Algorithms for Higher-Risk Disease
Hambley, B. C., & Dezern, A. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-51878-3_9
Treatment of Relapsed and Refractory AML: Non-intensive Approach in Unfit Patients
Récher, C. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-72676-8_12
Pathogenese und molekulare Diagnostik der akuten myeloischen Leukämie
Krämer, A., & Thiede, C. (2022) · Die Onkologie · doi:10.1007/s00761-022-01183-y
Identification and validation of signal recognition particle 14 as a prognostic biomarker predicting overall survival in patients with acute myeloid leukemiaPreprint
Shi, L., Huang, R., & Lai, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-481823/v1
Peer Review #2 of "Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes (v0.1)"
(2021) · PeerJ · doi:10.7287/peerj.11968v0.1/reviews/2
Peer Review #4 of "Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes (v0.2)"
(2021) · PeerJ · doi:10.7287/peerj.11968v0.2/reviews/4
Peer Review #3 of "Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes (v0.2)"
(2021) · PeerJ · doi:10.7287/peerj.11968v0.2/reviews/3
Peer Review #3 of "Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes (v0.1)"
(2021) · PeerJ · doi:10.7287/peerj.11968v0.1/reviews/3
TP53 Mutation in Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic SyndromePreprint
Niparuck, P., Police, P., Noikongdee, P., Siriputtanapong, K., Limsuwanachot, N., Rerkamnuaychoke, B., Chuncharunee, S., & Siriboonpiputtana, T. (2021) · Research Square · doi:10.21203/rs.3.rs-148593/v1
Peer Review #4 of "Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes (v0.1)"
(2021) · PeerJ · doi:10.7287/peerj.11968v0.1/reviews/4
Peer Review #1 of "Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes (v0.1)"
(2021) · PeerJ · doi:10.7287/peerj.11968v0.1/reviews/1
Pathogenetic value of TP53 point mutations in adult acute myeloid leukemia patients
Vinogradov, A. V., Rezaykin, A. V., Литвинова, Д. В., Loboda, A., Sazonov, S. V., & Sergeev, A. G. (2020) · Russian Journal of Immunology · doi:10.46235/1028-7221-264-pvo
Interpretable precision medicine for acute myeloid leukemia
Gimeno, M. (2023) · doi:10.15581/10171/65641
Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study
Fu, Y., Su, L., Li, Y., & Tan, Y.-H. (2023) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-023-00933-x
Additional file 2 of Identification and validation of signal recognition particle 14 as a prognostic biomarker predicting overall survival in patients with acute myeloid leukemia
Shi, L., Huang, R., & Lai, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14594481
Azvudine exhibits potent differentiation-inducing effect by targeting the TERT/p21 axis in acute myeloid leukemia
Kwon, C.-S., Lee, J., Jeon, B.-E., Kim, T., Lee, S. H., Shin, H., & Kim, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118215
Introduction to Cancer Treatment
Zonouzi, S. K., Razi, S., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_216
Allogeneic Hematopoietic Stem Cell Transplantation as a Platform to Treat Chemorefractory Acute Myeloid Leukemia in Adult Patients
Alzetta, D., Cavattoni, I., & Mosna, F. (2025) · Cancers · doi:10.3390/cancers17203285
Additional file 1 of Identification and validation of signal recognition particle 14 as a prognostic biomarker predicting overall survival in patients with acute myeloid leukemia
Shi, L., Huang, R., & Lai, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14594478
Additional file 3 of Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
Daver, N. G., Iqbal, S., Renard, C., Chan, R. J., Hasegawa, K., Hu, H., Tse, P., Yan, J., Zoratti, M. J., Xie, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617344
Additional file 2 of Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
Daver, N. G., Iqbal, S., Renard, C., Chan, R. J., Hasegawa, K., Hu, H., Tse, P., Yan, J., Zoratti, M. J., Xie, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617341
Additional file 1 of Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
Daver, N. G., Iqbal, S., Renard, C., Chan, R. J., Hasegawa, K., Hu, H., Tse, P., Yan, J., Zoratti, M. J., Xie, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617338
TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches
Deshpande, S., Li, W. F., Song, J., Forsberg, M., Cerchione, C., Martinelli, G., & Konopleva, M. Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1735418

Authors: Hunter, A. M., & Sallman, D. A.
Affiliations: University of South Florida (US)
Moffitt Cancer Center (US)
Corresponding author: Sallman, David A.
ORCID: Hunter, Anthony M.
Sallman, David A.
Venue: Best Practice & Research Clinical Haematology
Publisher: Elsevier BV
Published: 2019-06
Volume: 32
Issue: 2
Pages: 134-144
ISSN: 1521-6926 (ISSN-L)
DOI: 10.1016/j.beha.2019.05.004
OpenAlex: W2944248311
Cited by: 102
References: 132
Citations by year: 2026: 5 · 2025: 8 · 2024: 11 · 2023: 20 · 2022: 19 · 2021: 26 · 2020: 10 · 2019: 2
FWCI: 2.31
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Best Practice & Research Clinical Haematology (publishedVersion)
PubMed (publishedVersion)
Funders: Celgene
Jazz
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords: TP53 mutation, acute myeloid leukemia, therapy-related AML, complex karyotype, prognostic factors, chemoresistance, hypomethylating agents, allogeneic hematopoietic stem cell transplantation, novel therapeutic approaches, targeted therapy
MeSH terms: Humans, Mutation, Time Factors, Leukemia, Myeloid, Acute, Survival Rate, Tumor Suppressor Protein p53, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Current status and new treatment approaches in TP53 mutated AML

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks